As of 2025-05-15, the Intrinsic Value of Gracell Biotechnologies Inc (GRCL) is -4.33 USD. This GRCL valuation is based on the model Peter Lynch Fair Value. With the current market price of 10.25 USD, the upside of Gracell Biotechnologies Inc is -142.24%.
Based on its market price of 10.25 USD and our intrinsic valuation, Gracell Biotechnologies Inc (GRCL) is overvalued by 142.24%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.33 - -4.33 | -4.33 | -142.24% |
| P/E | (24.51) - (25.56) | (25.11) | -345.0% |
| DDM - Stable | (6.62) - (21.23) | (13.92) | -235.8% |
| DDM - Multi | (6.01) - (15.35) | (8.68) | -184.7% |
| Market Cap (mil) | 983.25 |
| Beta | 1.99 |
| Outstanding shares (mil) | 95.93 |
| Enterprise Value (mil) | 766.27 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.42% |
| Cost of Debt | 5.00% |
| WACC | 10.27% |